Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.Price: EUR 595.00
Impact Factor 2020: 3.909
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease.
The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease.
Authors: Masoumi, Ava | Goldenson, Ben | Ghirmai, Senait | Avagyan, Hripsime | Zaghi, Justin | Abel, Ken | Zheng, Xueying | Espinosa-Jeffrey, Araceli | Mahanian, Michelle | Liu, Phillip T. | Hewison, Martin | Mizwicki, Matthew | Cashman, John | Fiala, Milan
Article Type: Research Article
Abstract: Patients with Alzheimer's disease (AD) suffer from brain amyloidosis related to defective clearance of amyloid-β (Aβ) by the innate immune system. To improve the innate immune system of AD patients, we studied immune stimulation of macrophages by 1α,25(OH)2 -vitamin D3 (1,25D3) in combination with curcuminoids. AD patients' macrophages segregate into Type I (positively stimulated by curcuminoids regarding MGAT-III transcription) and Type II (not stimulated). In both Type I and Type II macrophages, 1,25D3 strongly stimulated Aβ phagocytosis and clearance while protecting against apoptosis. Certain synthetic curcuminoids in combination with 1,25D3 had additive effects on phagocytosis in Type I but not …Type II macrophages. In addition, we investigated the mechanisms of 1,25D3 and curcuminoids in macrophages. The 1,25D3 genomic antagonist analog MK inhibited 1,25D3 but not curcuminoid effects, suggesting that 1,25D3 acts through the genomic pathway. In silico, 1,25D3 showed preferential binding to the genomic pocket of the vitamin D receptor, whereas bisdemethoxycurcumin showed preference for the non-genomic pocket. 1,25D3 is a promising hormone for AD immunoprophylaxis because in Type I macrophages combined treatment with 1,25D3 and curcuminoids has additive effects, and in Type II macrophages 1,25D3 treatment is effective alone. Human macrophages are a new paradigm for testing immune therapies for AD. Show more
Keywords: Alzheimer's disease, amyloid-β, curcuminoids, 1α, 25-dihydroxyvitamin D3, macrophages, MGAT-III, phagocytosis, vitamin D
Citation: Journal of Alzheimer's Disease, vol. 17, no. 3, pp. 703-717, 2009
Article Type: Research Article
Citation: Journal of Alzheimer's Disease, vol. 17, no. 3, pp. 721-723, 2009
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
Free service line: 400 661 8717
Fax: +86 10 8446 7947
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]